| Patient | Wilma Mankiller |
|---|---|
| Date of birth | 1945-11-18 |
| Identifiers | MRN HR-ML052-SYN-TD; SSN (made up) 000-52-4183 |
| Document date | 1980-07-13 |
| Author | Rena Hawkfeather-Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review five weeks after thymectomy. [S]
Ms. Mankiller returns five weeks after a robotic thymectomy, with two nights in hospital and no postoperative weakness or breathing problem. The pathology showed thymic follicular hyperplasia and no thymoma. The port sites have healed, and she took acetaminophen, not anti-inflammatory medicines, for the pain. Her eyelids have not drooped for three weeks. She raised azathioprine to 100 mg daily after two weeks, as planned, by telephone. The blood tests planned for two, four and six weeks after starting azathioprine were not done: the orders were placed at this clinic, she was preparing for surgery, and no one followed them up. She has had no fever, sore throat, bruising or jaundice. She is back at work three days a week. Home blood pressure readings are about 118/76. [S]
| Element | Detail |
|---|---|
| Thymectomy | Robotic, five weeks ago; no thymoma; uneventful recovery |
| Strength | MG-ADL 2 |
| Azathioprine | 100 mg daily for eight weeks; the early blood tests were missed |
| Work | Three days a week |
| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No ptosis or double vision for three weeks |
| Respiratory | Negative | No breathlessness; mild ache at the port sites, settling |
| Constitutional | Negative | No fever, sore throat or night sweats |
| Integumentary | Negative | No bruising, jaundice or rash |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating | One tablet three times daily | Oral route | 1980-03-09 to 1980-03-23 | completed | S |
| Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals | One tablet four times daily while awake | Oral route | 1980-03-23 to 1980-10-12 | completed | S |
| Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg | Once each morning; dose as directed | Oral route | 1980-03-23 to 1980-07-13 | completed | S |
| Prednisone 5 mg oral tablet, tapering from 40 mg each morning by 5 mg every two to three weeks | Once each morning; dose as directed | Oral route | 1980-07-13 | active | S |
| Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily | Once daily; dose as directed | Oral route | 1980-05-04 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food | One tablet daily with food | Oral route | 1980-03-23 | active | S |
| Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 1980-03-23 | active | S |
| Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprine | One tablet on Monday, Wednesday and Friday | Oral route | 1980-05-04 to 1980-10-05 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain | One or two tablets up to three times daily as needed | Oral route | 1979-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1980-07-13 | Body height | 163 | cm | S |
| 1980-07-13 | Body weight | 64.8 | kg | S |
| 1980-07-13 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 1980-07-13 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1980-07-13 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1980-07-13 | Heart rate | 74 | /min | S |
| 1980-07-13 | Respiratory rate | 14 | /min | S |
| 1980-07-13 | Body temperature | 36.7 | Cel | S |
| 1980-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1980-07-13 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 11.6-15 g/dL | Normal | S |
| 1980-07-13 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1980-07-13 | Platelets [#/volume] in Blood by Automated count | 250 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1980-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1980-07-13 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 1980-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.79 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1980-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1980-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-45 U/L | Normal | S |
| 1980-07-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-43 U/L | Normal | S |
| 1980-07-13 | Forced vital capacity [Volume] Respiratory system | 3.4 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 1980-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 1980-07-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/80 mm Hg; weight 64.8 kg |
| Chest | Three healed port sites on the right; lungs clear |
| Eyes | No ptosis after one minute of upgaze |
| Neurological | Neck and limb strength 5 of 5 without fatigue |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | resolved | confirmed | H53.2 | S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis. |
| Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1934 | active | confirmed | G70.00 | S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D). |
| Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed | Q61.2 | S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic. |
| Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed | Z87.81 | S — The crash, the operations and the injuries are documented (D); the current function is synthetic. |
| Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infection | active | confirmed | Z79.52 | S — Synthetic treatment plan. |
| Azathioprine as steroid-sparing therapy, with blood count and liver test monitoring | active | confirmed | Z79.624 | S — Synthetic treatment plan. |
| Acquired absence of the thymus after robotic extended thymectomy for myasthenia gravis (pathology: thymic follicular hyperplasia, no thymoma) | active | confirmed | Z90.89 | S — Synthetic: recorded after the thymectomy; the sources name surgery among her treatments without saying which. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | MG-ADL score | Every visit | Completed today | 2 |
| Imaging | Forced vital capacity | Every visit while on dose changes and after thoracic surgery | Completed today | 3.40 L |
| Examination | Myasthenic crisis warning signs | Every visit | Completed today | None after surgery |
| Laboratory | Blood count on azathioprine | Every one to two weeks for the first two months, then every three months | Completed today | Hemoglobin 12.6 g/dL; white cells 6.2; platelets 250 |
| Laboratory | Liver tests, creatinine, potassium and glucose | With each blood count on azathioprine; potassium on trimethoprim-sulfamethoxazole | Completed today | ALT 26 and AST 24 U/L; creatinine 0.79 mg/dL; eGFR 101; potassium 4.3 mmol/L; glucose 96 mg/dL |
| Laboratory | Early azathioprine blood tests missed | Two, four and six weeks after starting | Deferred | Not done, a deviation from the protocol: the orders were placed here, she was preparing for surgery an hour's drive away, and no one followed up. Today's tests at ten weeks show no toxicity, so no harm resulted, but a low white count could have gone unnoticed. Corrective action: standing orders at the Cherokee Nation clinic near her home, with a nurse call for each result |
| Examination | Blood pressure and weight | Every visit | Completed today | 124/80 mm Hg; home about 118/76; weight 64.8 kg |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with azathioprine | Completed today | Continues; potassium 4.3 mmol/L |
| Medication safety | Glucocorticoid effects | Every visit | Completed today | Sleep shorter; weight up 3 kg since diagnosis; no infection |
| Survey | Depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 0 |
| Referral | Thymectomy | Once | Completed today | Done five weeks ago; no thymoma |
| Self-management | Laboratory access close to home | Each blood test | Completed today | Standing orders placed at the Cherokee Nation clinic |
Goal progress:
Guideline basis: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Wolfe GI, et al. Randomized Trial of Thymectomy in Myasthenia Gravis (MGTX). N Engl J Med 2016;375(6):511-522 (2016); KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025)
Follow-up: Blood count and liver tests at the Cherokee Nation clinic in two and six weeks. Preventive visit in six weeks. Review here in three months. Next scheduled visit 1980-08-24: periodic adult preventive visit. [S]